Enalees, a biotech company producing rapid molecular diagnostic tests for the veterinary profession based on an isothermal amplification technique (LAMP PCR), today announces that it has appointed Eric Germain to the position of managing director.
In his new role, Eric will provide support for company president and co-founder, Laurent Thiery, as the group continues on its path of growth and global expansion.
Eric Germain has more than 25 years’ experience in strategic and decision-making roles, which include being responsible for territorial expansion and economic development. After completing a master’s degree in biology at the Université d’Orsay in Paris, France, and spending his early career in the education sector, Eric Germain went on to various roles as managing director and chief of staff within both private groups and French public institutions including Genopole. In previous roles he has also promoted the creation of innovative businesses in the fields of genomics and the environment in the Paris area.
“We’re delighted to welcome Eric Germain to Enalees. He is exactly the kind of person that I want to have beside me. He joins us at a key strategic moment for Enalees, as we look to build our European and global operations, while continuing our search for funds to meet the market needs and our growth ambitions," said Laurent Thiery, president and co-founder of Enalees.
In 2022, Enalees opened its first European branch, in the UK, marking the first strategic step on its roadmap to establishing a European group specialized in rapid molecular diagnostic tests for the veterinary profession. Thanks to a €500,000 ($537K) subsidy from the Île-de-France region (France), the group also expanded its R&D team and took steps to strengthen its supply and production chains.
In 2023, Enalees plans to open a series of new branches in Europe and set up a new proteomic development and manufacturing facility at its Genopole site. Between now and 2024 the company will also continue to expand its sales team.